A-MAV™ Anterior Motion Segment Replacement
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this clinical trial is to collect safety and effectiveness data concerning the A-MAV™ Anterior Motion Segment Replacement device as a method of treating patients with lumbar degenerative disc disease at one level from L4-S1. Overall success will be the primary clinical endpoint.
| Condition | Intervention | Phase |
|---|---|---|
|
Spinal Diseases |
Device: A-MAV™ disc |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Prospective, Non-Randomized Pilot Clinical Investigation of the A-MAV™ Anterior Motion Segment Replacement in Patients With Lumbar Degenerative Disc Disease |
- Overall Success= Oswestry Disability Index success; Maintenance or improvement in neurological status; No serious AE classified as implant or implant/surgical procedure associated; No additional surgical procedure classified as a failure [ Time Frame: 24 Months ] [ Designated as safety issue: Yes ]
- Disc height; SF-36; Back Pain Status; Leg Pain Status; Patient Satisfaction; Patient Global Perceived Effect; Other Measurements-Radiographic; Return to Work; Doctor's Perception of Results [ Time Frame: 24 Months ] [ Designated as safety issue: Yes ]
| Enrollment: | 53 |
| Study Start Date: | December 2005 |
| Study Completion Date: | May 2010 |
| Primary Completion Date: | October 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: A-MAV™disc |
Device: A-MAV™ disc
The A-MAV™ device is a spinal arthroplasy system intended to replace a damaged spinal disc. It is inserted using an anterior surgical approach and aims to reduce low back pain and maintain disc height at the affected level.
Other Name: A-MAV™
|
Detailed Description:
For this clinical trial, there is only one treatment group- patients receiving the A-MAV™ Anterior Motion Segment Replacement via an anterior surgical approach in the lumbar region of the spine from L4-S1.
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Has back and/or radicular pain with degeneration of the disc as confirmed by patient history, physical examination, and radiographic studies with one or more of the following factors:
- instability as defined by > 5° angulation
- osteophyte formation of facet joints or vertebral endplates
- decreased disc height, on average by >2mm, relative to the next adjacent vertebral segment
- scarring/thickening of ligamentum flavum, annulus fibrosis, or facet joint capsule
- herniated nucleus pulposus
- facet joint degeneration/changes
- vacuum phenomenon
- Has single-level symptomatic degenerative involvement from L4-S1 requiring surgical treatment
- Has intact facet joints at the involved vertebral levels documented by CT and/or MRI
- Has preop Oswestry score≥30
- Has preop back pain score ≥8
- Age 18 to 70 yrs, inclusive and is skeletally mature
- Has not responded to non-operative treatment for 6 mos
- If child-bearing potential, patient is non-pregnant, non-nursing, and agrees not to become pregnant for 1 yr after surgery
- Is willing and able to comply with the study plan and sign the Patient Informed Consent Form
Exclusion Criteria:
- Has primary diagnosis of a spinal disorder other than DDD at involved level
- Had previous anterior lumbar spinal surgery at involved level
- Had previous posterior lumbar spinal fusion surgical procedure at involved level
- Had prior posterior lumbar surgery resulting in significant muscle/ligament morbidity, not including facet saving techniques
- Requires surgical intervention at more than 1 lumbar level
- Has severe pathology of facet joints of involved vertebral bodies
- Has facet arthritis or any posterior element insufficiency
- Has spondylolisthesis
- Has mid-sagittal stenosis of <8mm, based on remaining canal diameter
- Has rotatory scoliosis at involved level
- Has lumbar scoliosis with >11° sagittal plane deformity
- Had previous trauma to L4, L5, or S1 levels in compression or burst
- Meets any of the following criteria: Previous diagnosis of osteoporosis, osteopenia, or osteomalacia; postmenopausal Non-Black female over 60 yrs of age and weighs less than 140 pounds; postmenopausal female that has sustained a non-traumatic hip, spine or wrist fracture; male over age 60 that has sustained a non-traumatic hip or spine fracture. If Yes to any of these, a DEXA scan is required. If level of BMD is -3.5 or lower or -2.5 or lower with vertebral crush fracture, the patient is excluded
- Had previous lumbar spinal fusion at adjacent level
- Bone growth stimulator use in spine
- Has obesity defined by BMI greater than or equal to 40
- Has arachnoiditis
- Has a non-contained or extruded herniated nucleus pulposus with acute nerve root compression
- Has condition that requires postop medications that interfere with bone metabolism, such as chronic steroid use or prolonged use of non-steroidal anti-inflammatory drugs, excluding routine perioperative, non-steroidal anti-inflammatory drugs. Does not include low dose aspirin for prophylactic anticoagulation
- Has overt or active bacterial infection, either local or systemic and/or potential for bacteremia
- Has presence or prior history of malignancy (except for basal cell carcinoma of skin)
- Has documented metal allergy, titanium alloy intolerance or cobalt-chrome-molybdenum alloy
- Is mentally incompetent. If questionable, obtain psych consult
- Has a Waddell Signs of Inorganic Behavior score of 3 or greater
- Has chronic or acute renal and/or hepatic failure or prior history of renal and/or hepatic parenchymal disease
- Is prisoner
- Is pregnant
- Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug abuse
- Has history of autoimmune disease
- Has received treatment with an investigational therapy within 30 days prior to implantation surgery or treatment is planned during 24 months following the implantation surgery
- Has history of any endocrine or metabolic disorder known to affect osteogenesis
- Has any disease that would preclude accurate clinical evaluation
Contacts and Locations| United States, Georgia | |
| Hughston Clinic | |
| Columbus, Georgia, United States, 31908 | |
| United States, Missouri | |
| Orthopedic Center of St. Louis | |
| Chesterfield, Missouri, United States, 63017 | |
| United States, Texas | |
| Central Texas Spine | |
| Austin, Texas, United States, 78731 | |
More Information
No publications provided
| Responsible Party: | Medtronic Spinal and Biologics |
| ClinicalTrials.gov Identifier: | NCT00635934 History of Changes |
| Other Study ID Numbers: | P04-05 |
| Study First Received: | March 7, 2008 |
| Last Updated: | April 24, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Medtronic Spinal and Biologics:
|
Lumbar Degenerative Disc Disease at One Level from L4-S1 |
Additional relevant MeSH terms:
|
Spinal Diseases Intervertebral Disk Degeneration Bone Diseases Musculoskeletal Diseases |
ClinicalTrials.gov processed this record on May 23, 2013